The global immune thrombocytopenia treatment market is experiencing a period of significant development. This situation can be attributed to several factors, including an rising prevalence of immune thrombocytopenia worldwide and the release of novel treatment approaches. Furthermore, advancements in diagnostic techniques are supporting earlier dia